Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.55 |
| ▸ | TEK | Q02763 | 14/20 | 0.55 |
| ▸ | YES1 | P07947 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.51 |
| ▸ | AURKA | O14965 | 8/20 | 0.51 |
| ▸ | TPX2 | Q9ULW0 | 6/20 | 0.51 |
| ▸ | LCK | P06239 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894966 | 0.85 | TEK (0.64) | KDRTEKYES1AURKBAURKA | |
| SCHEMBL1265402 | 0.80 | TEK (0.70) | KDRTEKYES1AURKBAURKA | |
| SCHEMBL2294228 | 0.79 | KDR (0.73) | KDRTEKYES1AURKBAURKA | |
| SCHEMBL15215848 | 0.77 | KDR (0.68) | KDRTEKYES1AURKBAURKA | |
| SCHEMBL1265373 | 0.76 | KDR (0.69) | KDRTEKYES1AURKBAURKA | |
| SCHEMBL1264824 | 0.75 | KDR (0.66) | KDRTEKYES1AURKBAURKA | |
| SCHEMBL1265135 | 0.74 | KDR (0.64) | KDRTEKYES1AURKBAURKA | |
| SCHEMBL1264019 | 0.74 | KDR (0.66) | KDRTEKYES1AURKBAURKA | |
| SCHEMBL1264024 | 0.73 | KDR (0.63) | KDRTEKYES1AURKBAURKA | |
| SCHEMBL15841861 | 0.73 | KDR (0.69) | KDRTEKYES1AURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | GRK4, MAP4K5, GRK5 | KDR 42/4885TEK 145/4885YES1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.